|Articles|April 22, 2022
Nitrosamine Control: Understanding the New FDA and EMA Regulations
Author(s)SGS
This technical bulletin discusses major regulatory updates, introduced by the FDA and EMA, regarding nitrosamines and SGS proposed risk assessment method for compliance.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
First-in-Human Study Validates Safety of Next-Generation mRNA–LNP Platform
2
How CDMO Alliances Can Provide End-to-End Service that Reduces Drug Development Time and Costs
3
FDA Clears PharmaResearch IND for Nano-Based Cancer Drug PRD-101
4
High-Dose Nusinersen Slows Neurodegeneration in SMA Patients, Study Shows
5